Institute of HIV Disease Prevention and Control, Rwanda Biomedical Center, Kigali, Rwanda; Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital, University of Basel, Basel, Switzerland; Swiss Tropical and Public Health Institute, University of Basel, Switzerland.
Institute of HIV Disease Prevention and Control, Rwanda Biomedical Center, Kigali, Rwanda.
Lancet HIV. 2017 Oct;4(10):e457-e464. doi: 10.1016/S2352-3018(17)30124-8. Epub 2017 Aug 8.
In Rwanda, HIV prevalence among adults aged 15-49 years has been stable at 3% since 2005. The aim of this study was to characterise HIV incidence across Rwanda.
We did a nationally representative, prospective HIV incidence survey for the period of 2013-14, which used two-stage sampling. We randomly selected 492 villages in the first sampling stage and 14 households per village in the second stage. Participants completed a questionnaire and 14 140 people were tested for HIV. 13 728 participants were HIV negative, and were enrolled in the incidence cohort. Participants were retested and surveyed again after 12 months. Weights were calculated as the inverse of the probability to select the villages and the households.
The study period was from Nov 5, 2013, to Nov 15, 2014. Among 14 222 respondents from 6792 households, 14 140 were tested for HIV and 13 728 were HIV negative. Of 12 593 people who participated in the endpoint data collection activities, 5965 (47·4%) were men and the mean age was 30 years (SD 10·8). 11 237 (89·2%) participants lived in rural areas, 4826 (38·3%) were single, and 7140 (56·7%) were married or cohabitating. During the year, 35 participants had seroconversion, including 13 men and 22 women, resulting in an overall incidence of 0·27 per 100 person-years (95% CI 0·18-0·35). Incidence was 0·21 per 100 person-years (0·10-0·32) in men and 0·32 per 100 person-years (0·19-0·45) in women. Our findings suggested multiple breakouts, with multiple seroconversions occurring in three villages and two households. Incidence was higher in adults aged 36-45 years (0·37 per 100 person-years, 0·12-0·62; adjusted hazard ratio [aHR] 4·49, 95% CI 1·30-14·70) relative to those aged 16-25, higher in western province (0·57 per 100 person-years, 0·31-0·87; aHR 5·90, 1·33-25·28) relative to the northern province, and higher in urban areas (0·65 per 100 person-years, 0·23-1·07; aHR 3·10, 1·28-6·99) than in rural areas.
The incidence of HIV in Rwanda was higher than that previously estimated from models, with outbreaks seeming to contribute to the ongoing epidemic. Characterisation of incident infections can help the national HIV programmes to plan for preventive interventions tailored to the most at risk populations.
Global Fund to Fight HIV, Tuberculosis and Malaria, WHO Rwanda, UNAIDS Rwanda, and the Government of Rwanda.
自 2005 年以来,卢旺达 15-49 岁成年人的艾滋病毒流行率一直稳定在 3%。本研究旨在描述卢旺达的艾滋病毒发病率。
我们在 2013-14 年期间进行了一项全国代表性的、前瞻性的艾滋病毒发病率调查,该调查采用两阶段抽样。我们在第一阶段随机选择了 492 个村庄,在第二阶段每个村庄选择了 14 户家庭。参与者完成了一份问卷,共有 14140 人接受了艾滋病毒检测。13728 名参与者艾滋病毒检测呈阴性,被纳入发病率队列。参与者在 12 个月后再次接受检测和调查。计算权重的方法是将选择村庄和家庭的概率倒数。
研究期间为 2013 年 11 月 5 日至 2014 年 11 月 15 日。在来自 6792 户家庭的 14222 名受访者中,14140 人接受了艾滋病毒检测,13728 人艾滋病毒检测呈阴性。在 12593 名参加终点数据收集活动的人中,5965 人(47.4%)为男性,平均年龄为 30 岁(标准差 10.8)。11237 名参与者(89.2%)居住在农村地区,4826 名(38.3%)为单身,7140 名(56.7%)已婚或同居。在这一年中,有 35 名参与者发生血清转换,其中包括 13 名男性和 22 名女性,因此总发病率为每 100 人年 0.27(95%CI 0.18-0.35)。男性发病率为每 100 人年 0.21(0.10-0.32),女性发病率为每 100 人年 0.32(0.19-0.45)。我们的研究结果表明存在多个爆发,三个村庄和两个家庭中有多个血清转换。36-45 岁成年人的发病率(每 100 人年 0.37,0.12-0.62;调整后的危险比[aHR]4.49,95%CI 1.30-14.70)高于 16-25 岁的成年人,西部省(每 100 人年 0.57,0.31-0.87;aHR 5.90,1.33-25.28)高于北部省,城市地区(每 100 人年 0.65,0.23-1.07;aHR 3.10,1.28-6.99)高于农村地区。
卢旺达的艾滋病毒发病率高于此前根据模型估计的发病率,疫情爆发似乎是导致疫情持续的原因。对新感染病例的特征描述有助于国家艾滋病毒规划为最易受感染的人群制定有针对性的预防干预措施。
全球抗击艾滋病、结核病和疟疾基金、世界卫生组织卢旺达办事处、联合国艾滋病规划署卢旺达办事处和卢旺达政府。